Evaluating The Safety and Effectiveness of The NeoDisc™ Versus ACDF in Subjects With Single-Level Cervical Disc Disease (NeoDisc™)

May 30, 2012 updated by: NuVasive

A Pivotal, Multi-Center, Randomized, Controlled Trial Evaluating The Safety and Effectiveness of The NeoDisc™ Versus Instrumented Anterior Cervical Discectomy and Fusion (ACDF) in Subjects With Single-Level Cervical Disc Disease

The purpose of the study is to evaluate the safety and effectiveness of the NeoDisc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of single-level cervical disc disease, by demonstrating non-inferior comparative results at the 24 month follow-up period pertaining to (1) improvement in the Neck Disability Index (NDI) score, (2) revision/reoperation/removal rate, (3) complication rate, and (4) maintenance or improvement in neurologic status.

Study Overview

Detailed Description

The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy. Implantation of the device will result in artificial replacement of a pathologically damaged or surgically removed cervical disc. Use of the device also obviates the need to harvest bone graft from the patient's iliac crest, a common and painful part of current surgical techniques.

The NeoDisc is indicated for cervical spinal arthroplasty in skeletally mature subjects with symptomatic cervical disc disease at one level from C3 to C7. Symptomatic cervical disc disease is defined as image-confirmed herniated disc, spondylosis, and/or loss of disc height, with functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution).

Study Type

Interventional

Enrollment (Actual)

488

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • La Jolla, California, United States, 92037
        • San Diego Center for Spinal Disorders
      • Marina del Rey, California, United States, 90245
        • Diagnostic and Interventional Surgical Center
      • Santa Monica, California, United States, 90404
        • The Spine Institute
    • Colorado
      • Durango, Colorado, United States, 81301
        • Spine Colorado / Durango Orthopedic Associates
      • Loveland, Colorado, United States, 80538
        • Rocky Mountain Spine Arthroplasty (RMA Ortho)
    • Florida
      • Ft. Lauderdale, Florida, United States, 33308
        • Florida Spine Specialists
      • Gainsville, Florida, United States, 32605
        • Florida Research Network, LLC
      • Jacksonville, Florida, United States, 32207
        • Lyerly Baptist
    • Georgia
      • Savannah, Georgia, United States, 31405
        • Optim Healthcare
    • Illinois
      • Warrenville, Illinois, United States, 60555
        • OAD Orthopaedics
    • Indiana
      • Indianapolis, Indiana, United States, 46278
        • OrthoIndy
    • Missouri
      • Jefferson City, Missouri, United States, 65101
        • Spine Midwest, Inc
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Western Regional Spine Center for Brain and Spine Surgery
    • New Jersey
      • Mount Laurel, New Jersey, United States, 08054
        • Coastal Spine
    • North Carolina
      • Raleigh, North Carolina, United States, 27609
        • Capital Neurosurgery
    • Ohio
      • Chillicothe, Ohio, United States, 45601
        • Center for Advanced Orthopaedics/Adena Health Pavillon
      • Columbus, Ohio, United States, 43221
        • Neurological Associates
      • Westerville, Ohio, United States, 43081
        • Central Ohio Neurological Surgeons
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Orthopedic Spine Associates
      • Medford, Oregon, United States, 97504
        • Southern Oregon Orthopedics
    • Texas
      • Austin, Texas, United States, 78731
        • Central Texas Spine Institute
    • Utah
      • Salt Lake City, Utah, United States, 82124
        • Salt Lake Orthopaedic Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18-60 years of age (inclusive and skeletally mature)
  • Diagnosis of symptomatic cervical disc disease, defined as image- confirmed pathology: herniated disc, spondylosis, and/or loss of disc height. Spondylosis is defined as MRI or CT-confirmed disc dessication, loss of disc height, bridging osteophytes, and/or uncovertebral arthrosis. Loss of disc height is specified as a measurement of at least 25% less than an adjacent nonsymptomatic level, but with a minimum of 1mm height remaining.
  • Functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution)
  • Symptomatic level is C3-4, C4-5, C5-6 or C6-7 (one level)
  • Preop NDI ≥30 points
  • Unresponsive to conservative treatment for ≥6 wks, or exhibits progressive symptoms or signs of nerve root or spinal cord compression in the face of conservative treatment
  • Not pregnant, nor interested in becoming pregnant within the follow-up period of the study
  • Willing and able to comply with the requirements defined in the protocol for the duration of the study
  • Signed and dated Informed Consent

Exclusion Criteria:

  • Prior cervical fusion surgery at the operative level
  • Prior cervical laminectomy at the operative level (prior cervical laminotomy need not be excluded)
  • Prior cervical complete facetectomy at the operative level
  • Requiring surgical treatment that would leave the patient with a postoperative deficiency of the posterior elements
  • Radiographic signs of significant instability at operative level (greater than 3mm translation, > 11 degrees rotation different from adjacent level)
  • Bridging osteophytes or motion < 2 degrees
  • Radiographic confirmation of significant facet joint disease or degeneration
  • Chronic neck or arm pain of unknown etiology
  • Clinically significant symptomatic myelopathy (e.g., those with signal changes in the spinal cord on preoperative T2-weighted MRI)
  • Cervical fracture, anatomic anomaly, or deformity (e.g. ankylosing spondylitis, scoliosis) at the levels to which the prosthesis will be attached
  • Severe spondylolisthesis (>grade 1)
  • Endocrine disorders or connective tissue diseases
  • Rheumatoid arthritis or other autoimmune disease
  • Progressive neuromuscular disease, e.g., muscular dystrophy, multiple sclerosis
  • Chronic steroid users
  • Taking any medications or drugs that are known to potentially interfere with the bone metabolism or soft tissue healing, which may include (but is not limited to) the following: inhaled glucocorticoids for asthma, corticosteroids, thyroid hormones, blood thinners (heparin, warfarin), gonadotropin-releasing hormone agonists for prostate cancer treatment, contraceptive medroxyprogesterone, lithium for bi-polar disorder treatment, anticonvulsants, aluminum-containing antacids, tetracycline
  • Osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated (DEXA T-score less than or equal to -2.5; DEXA necessary only if patient exhibits risk factors for low bone mass as quantified in DEXA screening questionnaire).
  • Diabetes mellitus requiring insulin management
  • Presence of metastases or active spinal tumor malignancy
  • Body Mass Index (BMI) > 40
  • Active local or systemic infection, including AIDS, hepatitis
  • Having been enrolled in another investigational device study within the last 90 days
  • Having had another cervical device implanted that would interfere with the surgical approach, study or control device, or follow-up evaluations.
  • Demonstrates signs of nonorganic behavior, such as Waddell's signs
  • History of substance abuse
  • Involved in spinal litigation
  • Mentally incompetent
  • Incarcerated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
NeoDisc
The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
ACTIVE_COMPARATOR: 2
ACDF
Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Improve in NDI by ≥ 15 pnts at 24 mo compared to Baseline; No device failures requiring revision, re-op or removal; No major complications,i.e.,vascular or neurological injury; Maintenance or improvement of neurologic status
Time Frame: August 2010
August 2010

Secondary Outcome Measures

Outcome Measure
Time Frame
ROM; Fusion/migration of device; SF-36 imp of ≥15% at 24 months comp to Baseline; VAS imp of > 20 mm at 24 months comp to Baseline; Disc ht from lateral x-ray showing maintenance or imp from Baseline at 24
Time Frame: August 2010
August 2010

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Scott Kitchel, MD, Medical Monitor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2006

Primary Completion (ACTUAL)

August 1, 2010

Study Completion (ACTUAL)

March 1, 2012

Study Registration Dates

First Submitted

May 22, 2007

First Submitted That Met QC Criteria

May 22, 2007

First Posted (ESTIMATE)

May 24, 2007

Study Record Updates

Last Update Posted (ESTIMATE)

June 5, 2012

Last Update Submitted That Met QC Criteria

May 30, 2012

Last Verified

May 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Disc Degenerative Disorder

3
Subscribe